Cancer News and Research

Latest Cancer News and Research

PepTcell changes name to SEEK

PepTcell, a leading UK privately-owned drug-discovery group, today announced it is changing its name to SEEK.

1 Dec 2010

Regis Corporation raises $1 million for breast cancer research

Regis Corporation would like to thank their stylists, customers and business partners, who together helped raise over $1 million for the Regis Foundation for Breast Cancer Research during their annual October Clip for the Cure event. Regis Corporation, the global leader in beauty salons, hair restoration centers and cosmetology education, has been supporting the cause since 1990.

1 Dec 2010

New experimental device could offer effective treatment option for people with swallowing disorders

In what might be one of the world's first medicinal body piercings, UC Davis Health System surgeons announced today that they have successfully implanted an experimental device in the throat of a man that will enable him to manually control his ability to swallow.

1 Dec 2010

British Journal: Obesity, alcohol consumption may increase cancer risk

People should be warned that cancer is linked to obesity and alcohol, rather than urged to eat more fruit and vegetables to protect against the disease.

1 Dec 2010

New findings on folic acid supplementation reveal causes of low birth weight

Groundbreaking work by a team of UK scientists has identified, for the first time, a link between changes in the DNA of newborn babies, folic acid supplementation during pregnancy, and birth weight.

1 Dec 2010

Debiopharm recognised with European Biopharmaceuticals company of the year award

The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group™ (Debiopharm).

1 Dec 2010

Active surveillance improves quality of life in low-risk prostate cancer patients

In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment, according to a study in the December 1 issue of JAMA.

1 Dec 2010

Accelerator announces Series A Preferred Stock financing of Acylin

Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.

1 Dec 2010

'Margaret Foti Award' for best thesis in translational oncology established

The American Association for Cancer Research, in cooperation with the University of Catania Ph.D. Oncology Program and the Italian League Against Cancer of Catania, announces the establishment of the "Margaret Foti Award" for the best thesis in translational oncology. The first awards will be given on Dec. 2, 2010, in Catania, Italy.

1 Dec 2010

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that initial safety and efficacy data from its ongoing Phase II Study with resminostat, a pan-Histone Deacetylase (HDAC) Inhibitor, in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, USA.

1 Dec 2010

Scripps Research Institute enters agreement with Aileron Therapeutics

The Scripps Research Institute and Aileron Therapeutics today announced that they have entered into an agreement that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide technology.

1 Dec 2010

HOANNJ announces collaboration to enhance cancer care through United Network of US Oncology

Hematology Oncology Associates of Northern New Jersey, P.A. (HOANNJ), an independent physician-owned, single-specialty oncology practice with offices in Morristown and Parsippany, and US Oncology, Inc., the nation's leading integrated oncology company, today announced their new collaboration to protect, expand and enhance patient access to high-quality, evidence-based cancer care and clinical research through the United Network of US Oncology.

1 Dec 2010

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

1 Dec 2010

Experts suggest measure to raise awareness about skin cancer among retired population

Failure to get moles and skin changes checked out by a doctor has contributed to a steep rise in deaths from malignant melanoma among pensioners, experts warned today (Tuesday).

1 Dec 2010

China Medical Technologies prices $125 million convertible senior notes offering

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it increased the size of its previously announced offering of convertible senior notes. On November 30, 2010, the Company priced US$125 million in aggregate principal amount of convertible senior notes due 2016 at an issue price of 100%. The transaction is expected to close on December 6, 2010, subject to satisfaction of various customary closing conditions.

1 Dec 2010

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Cell Therapeutics, Inc. announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present end of study results for the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma at the 52nd Annual Meeting of the American Society of Hematology on Sunday, December 5, 2010 in Orlando, Florida.

1 Dec 2010

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson's disease, a debilitating neurological condition with considerable unmet need for new treatments.

1 Dec 2010

Precision Therapeutics to present abstracts on breast cancer therapy at San Antonio Symposium

Precision Therapeutics will present two abstracts at the 33rd Annual San Antonio Breast Cancer Symposium, which will be held December 8-12, 2010 in San Antonio, Texas.

1 Dec 2010

Research could lead to new drug treatment for metabolic diseases

A team of Harvard School of Public Health (HSPH) scientists report finding a molecular "switch" that can "turn off" some cellular processes that are protective against aging and metabolic diseases. While more research is needed, the findings may open doors for new drug treatments to halt or slow development of metabolic diseases like type 2 diabetes or heart disease. The research findings appear in the December 1, 2010 issue of Cell Metabolism.

1 Dec 2010

Vitamin D supplementation may reduce risk of diabetes, heart disease: Research

Researchers from the UC Davis Health System have found that compared with healthy controls, blood levels of vitamin D are significantly reduced in patients in the Sacramento area with metabolic syndrome, a constellation of disease risk factors that affects about one in three U.S. adults and predisposes them to diabetes, heart disease and stroke.

1 Dec 2010

Cancer News and Research

Latest Cancer News and Research

PepTcell changes name to SEEK

Regis Corporation raises $1 million for breast cancer research

New experimental device could offer effective treatment option for people with swallowing disorders

British Journal: Obesity, alcohol consumption may increase cancer risk

New findings on folic acid supplementation reveal causes of low birth weight

Debiopharm recognised with European Biopharmaceuticals company of the year award

Active surveillance improves quality of life in low-risk prostate cancer patients

Accelerator announces Series A Preferred Stock financing of Acylin

'Margaret Foti Award' for best thesis in translational oncology established

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

Scripps Research Institute enters agreement with Aileron Therapeutics

HOANNJ announces collaboration to enhance cancer care through United Network of US Oncology

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

Experts suggest measure to raise awareness about skin cancer among retired population

China Medical Technologies prices $125 million convertible senior notes offering

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

Precision Therapeutics to present abstracts on breast cancer therapy at San Antonio Symposium

Research could lead to new drug treatment for metabolic diseases

Vitamin D supplementation may reduce risk of diabetes, heart disease: Research

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in